Surgical Management of Amiodarone‐associated Thyrotoxicosis: Mayo Clinic Experience

• Published in: World journal of surgery 2004-11, Vol.28 (11), p.1083-1087
• Main Authors: Houghton, Scott G., Farley, David R., Brennan, Michael D., van Heerden, Jon A., Thompson, Geoffrey B., Grant, Clive S.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Amiodarone; Amiodarone - adverse effects; Amiodarone Treatment; Anti-Arrhythmia Agents - adverse effects; Antiarrhythmic Agent; Arrhythmias, Cardiac - drug therapy; Arrhythmias, Cardiac - epidemiology; Fatal Outcome; Female; Humans; Male; Middle Aged; Risk Factors; Symptomatic Hypocalcemia; Thyroidectomy; Thyrotoxicosis - chemically induced; Thyrotoxicosis - epidemiology; Thyrotoxicosis - surgery; Total Thyroidectomy
• ISSN: 0364-2313; 1432-2323
• DOI: 10.1007/s00268-004-7599-6

Amiodarone‐associated thyrotoxicosis (AAT) is often poorly tolerated owing to underlying cardiac disease, and it is frequently refractory to conventional medical treatment. The goal of this study was to describe the patient characteristics, management, and outcomes of all the patients treated surgically for AAT at a single institution. We conducted a retrospective chart review of all patients managed surgically for AAT (April 1985 through November 2002) at the Mayo Clinic in Rochester, Minnesota. Altogether, 29 men and 5 women, ages 39 to 85 years (median 60 years), treated with amiodarone for 3 to 108 months underwent near‐total or total thyroidectomy. Frequent symptoms were worsening heart failure, fatigue, weight loss, and tremor. Altogether, 12 patients failed medical management of their AAT, and 21 received no preoperative medical therapy. One patient had been successfully managed medically but required definitive treatment. Common indications for operation were the need to remain on amiodarone, cardiac decompensation, medically refractory disease, and severe symptoms, both hyperthyroid and cardiac, necessitating prompt resolution. The median ± SD American Society of Anesthesiologists (ASA) classification (1 = healthy through 5 = moribund) was 3.00 ± 0.58. A total of 27 specimens had histology consistent with AAT. Complications included death (n = 3), rehospitalization (n = 3), symptomatic hypocalcemia (n = 2), pneumonia (n = 2), cervical hematoma (n = 1), prolonged ventilatory wean (n = 1), and stroke (n = 1); one patient developed hypotension, adult respiratory distress syndrome, and sepsis. Of the 31 surviving patients, 25 (80%) remained on amiodarone postoperatively. The median follow‐up was 29 months, at which time all surviving patients were free of hyperthyroid symptoms. Thyroidectomy is an effective treatment for AAT but has a high incidence of perioperative morbidity and mortality. The cardiovascular co‐morbidities and high operative risk in this group of patients may account for the increased complication rate.